Coloplast A/S (CLPBY) to Release Earnings on Tuesday

Coloplast A/S (OTCMKTS:CLPBY) is anticipated to issue its quarterly earnings data on Tuesday, February 4th. Analysts expect Coloplast A/S to post earnings of $0.08 per share for the quarter. Coloplast A/S has set its FY 2025 guidance at EPS.

Coloplast A/S (OTCMKTS:CLPBY) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.08 EPS for the quarter. The company had revenue of $1.02 billion during the quarter. Coloplast A/S had a return on equity of 30.19% and a net margin of 18.69%. On average, analysts expect Coloplast A/S to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Coloplast A/S Price Performance

Shares of CLPBY stock opened at $11.51 on Monday. The firm’s 50-day simple moving average is $11.48 and its 200-day simple moving average is $12.58. The company has a current ratio of 1.02, a quick ratio of 0.66 and a debt-to-equity ratio of 0.92. Coloplast A/S has a 1-year low of $10.63 and a 1-year high of $14.34.

Coloplast A/S Increases Dividend

The business also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Monday, December 9th were paid a dividend of $0.2435 per share. The ex-dividend date was Monday, December 9th. This is an increase from Coloplast A/S’s previous dividend of $0.05. Coloplast A/S’s dividend payout ratio (DPR) is currently 93.94%.

Analyst Ratings Changes

CLPBY has been the subject of a number of research analyst reports. Sanford C. Bernstein upgraded Coloplast A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 28th. UBS Group upgraded Coloplast A/S from a “strong sell” rating to a “hold” rating in a research note on Wednesday, December 11th. Finally, Hsbc Global Res raised Coloplast A/S from a “moderate sell” rating to a “hold” rating in a research note on Monday, November 18th.

Coloplast A/S Company Profile

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments.